A Study Of PF-06647263 In Patients With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Neoplasms, Triple-Negative Breast Cancer

In brief

To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Key facts

Study ID

NCT02078752

Run by

Pfizer

People needed

60

Starts

2014-04-09

Expected to finish

2017-05-10

Last updated by the study team

2019-04-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available
• Performance Status of 0 or 1
• Adequate bone marrow, kidney, and liver function
• Part 2 includes advanced triple negative breast cancer patients.

You may not qualify if…

• Brain metastases requiring steroids
• Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
• Active and clinically significant bacterial, fungal or viral infection

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Brigham & Women's Hospital (BWH) — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute (DFCI) — Boston, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Comprehensive Cancer Centers Of Nevada — Las Vegas, Nevada, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Tennessee Oncology, PLLC — Nashville, Tennessee, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Huntsman Cancer Hospital / University of Utah — Salt Lake City, Utah, United States
• Huntsman Cancer Institute-University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.